Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adult Congenital Heart Disease: later-stage trial registry
3 of 3 indexed Adult Congenital Heart Disease trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Adult Congenital Heart Disease: 3 US clinical trials tracked, 3 recruiting.
Adult Congenital Heart Disease is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Anita Saraf, running 1 of these trials.
Enrollment posture brief
Registry condition adult-congenital-heart-disease
OPEN 3 | RECR 100% | LATE 1 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Adult Congenital Heart Disease lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adult Congenital Heart Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adult Congenital Heart Disease is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
Children's Hospital Medical Center, Cincinnati
NCT07477197
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Leiden University Medical Center
NCT06932081
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
Anita Saraf
NCT06260059
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Adult Congenital Heart Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adult Congenital Heart Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adult Congenital Heart Disease page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Adult Congenital Heart Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Anita Saraf sponsors the most Adult Congenital Heart Disease trials on record, review their full trial history before evaluating a specific study. See Anita Saraf's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult Congenital Heart Disease condition card totals 3 registered trials; most-linked intervention SGLT2 inhibitors; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.